| Identification | Back Directory | [Name]
(R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one | [CAS]
1971920-73-6 | [Synonyms]
PRN-2246
SAR442168
Tolebrutinib
(R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one
(R,E)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(penta-2,4-dien-2-yloxy)phenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one
2H-Imidazo[4,5-c]pyridin-2-one, 4-amino-1,3-dihydro-1-[(3R)-1-(1-oxo-2-propen-1-yl)-3-piperidinyl]-3-(4-phenoxyphenyl)- | [Molecular Formula]
C26H25N5O3 | [MDL Number]
MFCD32710277 | [MOL File]
1971920-73-6.mol | [Molecular Weight]
455.51 |
| Chemical Properties | Back Directory | [Boiling point ]
698.1±65.0 °C(Predicted) | [density ]
1.334±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (219.53 mM; Need ultrasonic) | [form ]
Solid | [pka]
7.03±0.20(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Tolebrutinib is a drug candidate; used in preparation of Dihydroimidazopyridine derivatives for treatment of Bruton''s tyrosine kinase related diseases. | [in vivo]
PRN2246 (1-5 mg/kg; p.o. q.d. for 28 d) produces dose-dependent protection from in myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) model[2]. |
|
|